Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

This study is testing whether a simpler two-drug HIV treatment — dolutegravir plus lamivudine — is safe and effective for people with HIV who are also being treated for tuberculosis (TB) using the antibiotic rifampin. **You may be eligible if...** - You have confirmed HIV-1 infection (documented by standard HIV tests or viral load) - You have active tuberculosis (TB) and are currently being treated with a rifampin-based TB regimen - You are not yet on HIV treatment (antiretroviral therapy naïve) - You meet blood count and organ function requirements **You may NOT be eligible if...** - You have previously been on HIV treatment (antiretroviral drugs) - You have resistance to any of the study drugs - You are pregnant or planning to become pregnant - You have serious liver, kidney, or other health complications that would interfere with the study Talk to your doctor to see if this trial is right for you.